Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

The tablet could be a cheaper and more convenient alternative to injections

The Independent UK

‘Shock’ as study reveals how weight-loss pill stacks up against injections

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

The Independent UK

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Trump officials plan coverage for weight loss drugs under Medicare and Medicaid

Pilot program, first pitched under Biden, will cover GLP-1 drugs such as Ozempic to address chronic obesity in US

The Guardian - US

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

inkl

Read news from The Economist, FT, and more,
with one subscription

EU regulator backs new Alzheimer’s treatment, reversing initial decision to reject it

EU regulator backs new Alzheimer’s treatment, reversing initial decision to reject it

An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s disease.

Wellness Stocks to Invest in Now

Wellness Stocks to Invest in Now

Breakthroughs that help us live longer, healthier lives can also create opportunities for investors.

Experimental treatment for high cholesterol edits DNA in the body to reduce LDL

Experimental treatment for high cholesterol edits DNA in the body to reduce LDL

An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific cholesterol-raising conditions.

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

Are Growth Stocks Back? 3 That Look Like Winners to Buy Now

Are Growth Stocks Back? 3 That Look Like Winners to Buy Now

Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Weight-loss jabs linked to hundreds of cases of life-threatening illness and 10 deaths

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking them, figures from the UK’s medicines regulator reveal

The Independent UK

‘I was diagnosed with potentially deadly condition after taking weight-loss jab now offered on NHS’

Exclusive: Julie Bishop lost two-and-a-half stone in eight weeks by taking Mounjaro before she was sent to hospital with pancreatitis and told to stop taking the weight-loss jab

The Guardian - UK

Hundreds of weight loss and diabetes jab users report pancreas problems

UK health officials launch study into side-effects of weight loss drugs after increased reports of acute pancreatitis

Evening Standard

Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.

Get all your
news in one place.

100's of premium titles.
One news app.

Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

Meta Platforms and Eli Lilly are two stocks that could perform stock splits down the road, and it's not just because of their high share prices.

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices

Despite Trump’s executive order to cut drug prices, Eli Lilly’s stock surged, showing strong resilience and impressive gains amidst regulatory concerns.

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

1 … 5 6 7 8

People

180,480 stories

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Executive Order

Alzheimer Disease

Places

360,832 stories

136,070 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play